ArticleInternational journal of nanomedicine2013
Fabrication of small-diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to improve graft patency.
Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Comparative evaluation of cell types for endothelialization in cardiovascular tissue engineering.Iranian journal of basic medical sciences · 2026Review
- Synthesis of Flexible Random Copolymers of Poly(butyleneBiomacromolecules · 2025Article
- Impact of uniaxial cyclic stretching on matrix-associated endothelial cell responses.Materials today. Bio · 2024Article
- Enhanced hemocompatibility and rapid magnetic anastomosis of electrospun small-diameter artificial vascular grafts.Frontiers in bioengineering and biotechnology · 2024Article
- Nerve ECM and PLA-PCL based electrospun bilayer nerve conduit for nerve regeneration.Frontiers in bioengineering and biotechnology · 2023Article
- Role of animal models in biomedical research: a review.Laboratory animal research · 2022Review
- Updated perspectives on vascular cell specification and pluripotent stem cell-derived vascular organoids for studying vasculopathies.Cardiovascular research · 2022Review
- Electrospun nanofiber scaffold for vascular tissue engineering.Materials science & engineering. C, Materials for biological applications · 2021Review
- Selection of different endothelialization modes and different seed cells for tissue-engineered vascular graft.Bioactive materials · 2021Review
- Glycosaminoglycans: From Vascular Physiology to Tissue Engineering Applications.Frontiers in chemistry · 2021Review
- Fabrication of Kidney Proximal Tubule Grafts Using Biofunctionalized Electrospun Polymer Scaffolds.Macromolecular bioscience · 2019Article
- Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.Advanced healthcare materials · 2018Review
- Review of Vascular Graft Studies in Large Animal Models.Tissue engineering. Part B, Reviews · 2018Review
- Tissue engineered vascular grafts for pediatric cardiac surgery.Translational pediatrics · 2018Review
- Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering.Frontiers in pharmacology · 2018Review
- Biomechanical Comparison of Glutaraldehyde-Crosslinked Gelatin Fibrinogen Electrospun Scaffolds to Porcine Coronary Arteries.Journal of biomechanical engineering · 2016Article
- Greener synthesis of electrospun collagen/hydroxyapatite composite fibers with an excellent microstructure for bone tissue engineering.International journal of nanomedicine · 2015Article
- Scaffolds in vascular regeneration: current status.Vascular health and risk management · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The poor patency rate following small-diameter vascular grafting remains a major hurdle for the widespread clinical application of artificial blood vessels to date. Our previous studies found that electrospun poly(L-lactide-co-epsilon-caprolactone) (P[LLA-CL]) nanofibers facilitated the attachment and growth of endothelial cells (EC), and heparin incorporated into P(LLA-CL) nanofibers was able to release in a controlled manner. Hence, we hypothesized that heparin-bonded P(LLA-CL) vascular scaffolds with autologous EC pre-endothelialization could significantly promote the graft patency rate. To construct a small-diameter vascular scaffold, the inner layer was fabricated by heparin-bonded P(LLA-CL) nanofibers through coaxial electrospinning, while the outer layer was woven by pure P(LLA-CL) nanofibers. Except dynamic compliance (5.4 1.7 versus 12.8 2.4×10(-4)/mmHg, P<0.05), maximal tensile strength, burst pressure, and suture retention of the composite, scaffolds were comparable to those of canine femoral arteries. In vitro studies indicated that the scaffolds can continuously release heparin for at least 12 weeks and obtain desirable endothelialization through dynamic incubation, which was confirmed by EC viability and proliferation assay and scanning electronic microscopy. Furthermore, in vivo studies demonstrated that pre-endothelialization by autologous ECs provided a better effect on graft patency rate in comparison with heparin loading, and the united application of pre-endothelialization and heparin loading markedly promoted the 24 weeks patency rate of P(LLA-CL) scaffolds (88.9% versus 12.5% in the control group, P<0.05) in the canine femoral artery replacement model. These results suggest that heparin-bonded P(LLA-CL) scaffolds have similar biomechanical properties to those of native arteries and possess a multiporous and biocompatible surface to achieve satisfactory endothelialization in vitro. Heparin-bonded P(LLA-CL) scaffolds with autologous EC pre-endothelialization have the potential to be substitutes for natural small-diameter vessels in planned vascular bypass surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.